Italia markets closed
Dow Jones
38.702,93 +113,77 (+0,29%) Nasdaq
17.778,83 +89,95 (+0,51%) Nikkei 225
38.102,44 -712,12 (-1,83%) EUR/USD
1,0728 +0,0020 (+0,18%) Bitcoin EUR
61.343,09 -702,42 (-1,13%) CMC Crypto 200
1.363,63 -24,53 (-1,76%)
NBIX Oct 2024 140.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 03:14PM EDT. Mercato aperto.
| Chiusura precedente | 10,30 |
| Aperto | 10,30 |
| Denaro | 12,80 |
| Domanda | 16,20 |
| Prezzo d'esercizio | 140,00 |
| Scadenza | 2024-10-18 |
| Min-Max giorno | 10,30 - 10,30 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 190 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.